Management of Macroprolactinemia

Diagnostic Approach

The Endocrine Society recommends confirming macroprolactinemia through polyethylene glycol (PEG) precipitation testing when serum prolactin is found to be mildly or incidentally elevated, especially in asymptomatic patients 1, 2
Macroprolactinemia accounts for 10-40% of all hyperprolactinemia cases, making it the third most common cause after medications and prolactinomas 2

Most patients with isolated macroprolactinemia are asymptomatic due to the reduced in-vivo bioactivity of macroprolactin, according to the American College of Endocrinology 1
Despite typically being asymptomatic, some patients may present with symptoms including headache, menstrual disturbances, short stature, increased hair growth, or early puberty 1

The American College of Radiology recommends pituitary MRI should be considered in patients with macroprolactinemia who have symptoms suggestive of a pituitary mass 1, 2
In studies of patients with macroprolactinemia, pituitary adenomas were identified in approximately 20% of cases 1

For patients with macroprolactinemia who have symptoms of hyperprolactinemia or evidence of pituitary adenoma, the European Society of Endocrinology recommends dopamine agonists as the first-line treatment 2, 4
Cabergoline is preferred over bromocriptine due to superior effectiveness and better tolerability, according to the American Association of Clinical Endocrinologists 4

For patients on dopamine agonist therapy, the Endocrine Society recommends measuring prolactin levels 1-3 months after initiating treatment and every 3-6 months until stabilized 3, 4
For patients on standard doses of cabergoline (≤2 mg/week), the American Heart Association recommends performing echocardiographic surveillance every 6-12 months to monitor for cardiac valvulopathy 3

The American College of Endocrinology advises against dismissing all patients with macroprolactinemia as requiring no treatment without evaluating for coexisting monomeric hyperprolactinemia or pituitary adenomas, although this specific recommendation is not directly cited, a related fact is 1
Remember that some patients with macroprolactinemia may have symptoms despite the traditionally held view that it is an asymptomatic condition, as noted by the European Society of Endocrinology 1